|
|
|
| home > ebr > summer 2003 > maximising return on investment with r&d portfolio management |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
| Product prioritisation at a tactical level - identifying the most desirable and attractive products in a company's R&D pipeline - remains the primary focus of portfolio management today. This factor, coupled with the need to maximise return on investment, acts as a strong driving force for pharmaceutical companies to perform portfolio management. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
World Vaccine Congress
10-12 April 2012, Gaylord National Hotel and Convention Center, Washington, US
The 12th annual World Vaccine Congress Washington brings new scientific and business critical debate, discussion and solutions from the true global pioneers shaping vaccine R&D.
More info >> |
|
 |
News and Press Releases |
 |
APTAR PHARMA’S PRESERVATIVE-FREE MULTIDOSE DISPENSER OSD CHOSEN FOR THE FIRST TIME FOR AN EYE CARE PRODUCT
Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser (OSD) has found its first application for the treatment of dry eye with the launch of VISMED® MULTI. Aptar Pharma has worked closely with the Swiss-German based Eye Care specialist TRB Chemedica for improving patient safety, achieving dosing accuracy and maintaining product stability on the ophthalmic spray device.
More info >> |
|
|
